Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, circulation of indigenous wild poliovirus (WPV) has continued without interruption in only three countries: Afghanistan, Nigeria, and Pakistan. During April-December 2013, a polio outbreak caused by WPV type 1 (WPV1) of Nigerian origin resulted in 217 cases in or near the Horn of Africa, including 194 cases in Somalia, 14 cases in Kenya, and nine cases in Ethiopia (all cases were reported as of March 10, 2014). During December 14-18, 2013, Kenya conducted the first-ever campaign providing inactivated poliovirus vaccine (IPV) together with oral poliovirus vaccine (OPV) as part of its outbreak response. The campaign targeted 126,000 children aged ≤59 months who resided in Somali refugee camps and surrounding communities near the Kenya-Somalia border, where most WPV1 cases had been reported, with the aim of increasing population immunity levels to ensure interruption of any residual WPV transmission and prevent spread from potential new importations. A campaign evaluation and vaccination coverage survey demonstrated that combined administration of IPV and OPV in a mass campaign is feasible and can achieve coverage >90%, although combined IPV and OPV campaigns come at a higher cost than OPV-only campaigns and require particular attention to vaccinator training and supervision. Future operational studies could assess the impact on population immunity and the cost-effectiveness of combined IPV and OPV campaigns to accelerate interruption of poliovirus transmission during polio outbreaks and in certain areas in which WPV circulation is endemic.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584634 | PMC |
J Appl Microbiol
December 2024
Enteric Virus Laboratory, Department of Genetics, Microbiology and Statistics, School of Biology.
Enteroviruses (EV) are a highly diverse group of viruses multiplying primarily in the gastrointestinal tract and/or the upper respiratory tract, initially distributed in two separate genera: Enterovirus and Rhinovirus, respectively. According to the similarities in genome organization and particle structure, rhinovirus species were later reclassified as also belonging to genus Enterovirus. Human EV infections are usually asymptomatic or causing mild clinical manifestations.
View Article and Find Full Text PDFTher Adv Infect Dis
November 2024
Independent Consultant, Minneapolis, MN, USA.
International spread of polio continues to be a Public Health Emergency of International Concern since its declaration by the World Health Organization in 2014 and its reiteration in 2024. In 2023 and 2024, two countries remained endemic for wild poliovirus (WPV) but 20 countries reported polio outbreaks due to vaccine-derived polioviruses (VDPVs) in 2023 and 10 countries in 2024 (up to mid-June). Guidelines from various agencies recommend polio vaccination before travelling to or from polio-affected countries, or attending mass gatherings anywhere in the world, particularly if the crowd is international.
View Article and Find Full Text PDFNPJ Vaccines
November 2024
Biological Mimetics Inc., 124 Byte Drive, 21702, Frederick, MD, USA.
Despite their efficacy, the currently available polio vaccines, oral polio vaccine (OPV) and inactivated polio vaccine (IPV), possess inherent flaws posing significant challenges in the global eradication of polio. OPV, which uses live Sabin attenuated strains, carries the risk of reversion to pathogenic forms and causing vaccine-associated paralytic poliomyelitis (VAPP) and vaccine-derived polio disease (VDPD) in incompletely vaccinated or immune-compromised individuals. Conventional IPVs, which are non-replicative, are more expensive to manufacture and introduce biohazard and biosecurity risks due to the use of neuropathogenic strains in production.
View Article and Find Full Text PDFClin Microbiol Infect
October 2024
The Hong Kong Jockey Club Global Health Institute, Hong Kong Special Administrative Region, P. R. China; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, P. R. China; Laboratory of Data Discovery for Health Limited (D(2)4H), Hong Kong Science Park, Hong Kong Special Administrative Region, P. R. China; The University of Hong Kong-Shenzhen Hospital, Shenzhen, P. R. China.
Objectives: This study aimed to assess the long-term persistence of neutralizing antibodies (nAb) titres and seroprotection proportions after the fourth and fifth doses of inactivated polio vaccine (IPV).
Methods: Serum samples from 299 children in Hong Kong were collected and used to estimate the persistence of nAb titres and seroprotection proportions by neutralisation test.
Results: The mean nAb titres against poliovirus types 1, 2, and 3 (PV1, PV2, and PV3) 1 month after receiving the fourth dose of IPV at 19 months of age were 2068 (95% credible interval, 1517-2864); 4705 (3439-6436); and 2758 (1894-4086); respectively, but declined substantially in 4 years to 268 (222-325), 751 (630-900), and 411 (323-521), respectively.
BMC Health Serv Res
October 2024
Videnza Consultores, Lima, Peru.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!